ImageneBio Inc (IMA) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
ImageneBio Inc (IMA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $66.9M, listed on NASDAQ, employing roughly 10 people, carrying a beta of 0.74 to the broader market. Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis Led by Kristin Yarema, public since 1998-02-27.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for IMA as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.